Triple threat: targeted drugs + CAR-T cells aim to beat a tough leukemia
NCT ID NCT06481228
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is testing a new treatment approach for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines targeted drugs (olverembatinib and venetoclax) with reduced-intensity chemotherapy, followed by CAR-T cell therapy. The goal is to achieve deeper remission, reduce the need for multiple chemotherapy cycles, and improve survival and quality of life. The study will enroll 82 participants and track outcomes like disease-free survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells, venetoclax, and olverembatinib
- What this could lead to
- If successful, this approach could offer a more effective and less toxic first-line treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia, potentially improving long-term survival and quality of life.
- What could go wrong
- This is an early-phase study with a small number of participants (82). The combination therapy may cause unexpected side effects, and the long-term benefits are not yet proven. CAR-T cell therapy carries risks like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- New drug cocktail targets tough leukemia
- Leukemia Patients' hidden threat: fungal infections under microscope
- New combo therapy aims to boost survival in adult leukemia
- New combo therapy aims to cut chemo and boost survival in leukemia
- New pill shows promise for leukemia patients who've run out of options